No robust evidence of lumefantrine resistance.
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA kamal.hamed@novartis.com.
Kamal
http://orcid.org/0000-0003-1896-9736
K
Hamed
Genomics Institute of the Novartis Research Foundation, San Diego, California, USA.
Kelli
K
Kuhen
D037621:Artemisinins / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use*
D037621:Artemisinins; D004983:Ethanolamines; D005449:Fluorenes; D011804:Quinolines